

EQA round: CSFK1/25 - Cerebrospinal Fluid Diagnostics

Deadline: 7.2.2025

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average

AV = assigned value

D_{max} = acceptable difference

SD = standard deviation

CVP = consensus of all participants

LL = lower limit

CV = coefficient of variation

U_{AV} = expanded uncertainty of the assigned value (k = 2)

UL = upper limit

N_{tot} = total number of the resultsN_{eva} = number of the results assessedN_{out} = number of the results removed before calculationN_{suc} = number of successful resultsS_{rel} = relative success

| Test Sample Group | [unit] | RoM | SD | CV [%] | N _{tot} | N _{out} | Comparability | | | | | N _{eva} | N _{suc} | S _{rel} [%] | |
|-----------------------------------|----------------------|------|-------|-----------|------------------|------------------|---------------|--|------------------|-------|------|------------------|------------------|-------------------------|-----|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | | |
| (398) Albumin | [mg/L] | | | | 11 | | | | | | | 11 | 11 | 100 | |
| Sample K | | 205 | 17 | 8,1 | 11 | | CVP | 200 | 5,7 | 23% | 154 | 246 | 11 | 11 | 100 |
| Other | | | | | 11 | 0 | | 1x 12, 1x 58, 3x 60, 2x 91, 2x 149, 1x 162, 1x 179 | | | | | 11 | | |
| (396) Glucose | [mmol/L] | | | | 11 | | | | | | | | 11 | 11 | 100 |
| Sample K | | 3,02 | 0,11 | 3,7 | 11 | | CVP | 3,04 | 0,037 | 18% | 2,49 | 3,59 | 11 | 11 | 100 |
| Other | | | | | 11 | 0 | | 1x 0, 2x 46, 3x 58, 3x 60, 1x 75, 1x 188 | | | | | 11 | | |
| (401) IgA | [mg/L] | | | | 5 | | | | | | | | 5 | 5 | 100 |
| Sample K | | 5,05 | 0,75 | 15 | 5 | | CVP | 4,97 | 0,2 | 32% | 3,37 | 6,57 | 5 | 5 | 100 |
| Other | | | | | 5 | 0 | | 1x 12, 2x 91, 2x 149 | | | | | 5 | | |
| (399) IgG | [mg/L] | | | | 10 | | | | | | | | 10 | 10 | 100 |
| Sample K | | 20,9 | 2,7 | 13 | 10 | | CVP | 20,5 | 0,71 | 24% | 15,5 | 25,5 | 10 | 10 | 100 |
| Other | | | | | 10 | 0 | | 1x 12, 2x 60, 3x 91, 3x 149, 1x 162 | | | | | 10 | | |
| (402) IgM | [mg/L] | | | | 5 | | | | | | | | 5 | 5 | 100 |
| Sample K | | 2,88 | 0,11 | 4 | 5 | | CVP | 2,95 | 0,093 | 31% | 2,03 | 3,87 | 5 | 5 | 100 |
| Other | | | | | 5 | 0 | | 1x 12, 2x 91, 2x 149 | | | | | 5 | | |
| (411) Intrathec. synt. IgA | [mg/L] | | | | 4 | | | | | | | | 4 | 4 | 100 |
| Sample K | | 0 | 0 | 0 | 4 | | CVP | 0 | | asym. | 0 | 1 | 4 | 4 | 100 |
| Other | | | | | 4 | 0 | | 4x 0 | | | | | 4 | | |
| (410) Intrathec. synt. IgG | [mg/L] | | | | 10 | | | | | | | | 10 | 9 | 90 |
| Sample K | | | | | 10 | | | | | | | | 10 | 9 | 90 |
| (0) not specified | | 0 | 0 | | 10 | 1 | CVP | 0 | | asym. | 0 | 1 | 10 | | |
| (412) Intrathec. synt. IgM | [mg/L] | | | | 4 | | | | | | | | 4 | 4 | 100 |
| Sample K | | 0 | 0 | 0 | 4 | | CVP | 0 | | asym. | 0 | 1 | 4 | 4 | 100 |
| Other | | | | | 4 | 0 | | 4x 0 | | | | | 4 | | |
| (403) Lactate | [mmol/L] | | | | 11 | | | | | | | | 11 | 11 | 100 |
| Sample K | | 1,47 | 0,096 | 6,5 | 11 | | CVP | 1,48 | 0,024 | 20% | 1,18 | 1,78 | 11 | 11 | 100 |
| Other | | | | | 11 | 0 | | 1x 1, 2x 58, 4x 60, 1x 75, 1x 178, 2x 188 | | | | | 11 | | |
| (413) Barrier permeability | [·10 ⁻³] | | | | 11 | | | | | | | | 11 | 11 | 100 |
| Sample K | | | | | 11 | | | | | | | | 11 | 11 | 100 |
| (0) not specified | | 5,12 | 0,41 | 8 | 11 | 0 | CVP | 5 | 0,14 | 25% | 3,75 | 6,25 | 11 | | |